REM Suppression Medications for REM Sleep Behavior Disorder
Primary REM Suppression Medications
- The American Academy of Sleep Medicine recommends clonazepam (0.25-2.0 mg at bedtime) as a first-line treatment for REM sleep behavior disorder (RBD), effective in approximately 90% of cases by promoting GABAergic inhibition through increased frequency of chloride channel opening 1, 3
- The American Academy of Sleep Medicine also recommends melatonin (3-15 mg at bedtime) as a first-line treatment for RBD, which binds to M1 and M2 receptors, suppressing REM sleep motor tone and normalizing circadian features of REM sleep 2
Secondary REM Suppression Medications
- The American Geriatrics Society suggests that tricyclic antidepressants, such as amitriptyline, may be used to treat RBD, although evidence is limited 5
- The American Academy of Sleep Medicine notes that SSRIs, such as paroxetine, may help treat cataplexy and REM sleep intrusion symptoms in patients with RBD 5
- The American Academy of Sleep Medicine recommends caution when using antidepressants, as some may paradoxically induce or worsen RBD symptoms 3
Medication Selection Considerations
- For isolated RBD, the American Academy of Sleep Medicine recommends clonazepam or melatonin as first-line treatments 1, 6
- For RBD with cognitive impairment, the American Academy of Sleep Medicine suggests considering acetylcholinesterase inhibitors, such as rivastigmine or donepezil 2
- For RBD with periodic limb movements, the American Academy of Sleep Medicine notes that pramipexole may be beneficial 2
Monitoring and Adjustments
- The American Academy of Sleep Medicine recommends monitoring patients for cognitive, motor, and autonomic deficits, as those with isolated RBD are at high risk for developing neurodegenerative disorders 2
- The American Academy of Sleep Medicine suggests that older adults may be more susceptible to side effects of benzodiazepines and require lower doses 2
- The American Academy of Sleep Medicine notes that combination therapy, such as clonazepam plus melatonin, is common in clinical practice for inadequate monotherapy response, although evidence for combinations is limited 2